San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) saw its shares edge up 3.6% to $19.95, after it released results from the Phase III GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (interleukin (IL)-36R MAb) in patients with generalized pustular psoriasis (GPP) flares.
AnaptysBio noted that the investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile. The drug has previously disappointed in an earlier trial in severe palmoplantar pustulosis and in the treatment of moderate-to-severe acne.
Results showed that 53.3% of the 15 patients who received the 750mg dose achieved GPPPGA 0/1 (clear or almost clear) at week four compared with 13.3% of the 15 patients on placebo. Additionally, 66.7% of the placebo group exited the trial early, crossed-over to the GEMINI-2 trial and were eligible to receive rescue therapy with a single dose of 750mg IV imsidolimab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze